PERSONALISED MEDICINE AND ITS IMPACT ON DRUG DEVELOPMENT, AUTHORIZATION AND CLINICAL PRACTICE

被引：0
|
作者：
del Barrio, J. [1 ]
机构：
[1] Roche Inst, Madrid, Spain
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2011年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [21] Pharmacogenomics in clinical practice and drug development
    Andrew R Harper
    Eric J Topol
    Nature Biotechnology, 2012, 30 : 1117 - 1124
  • [22] Pharmacogenomics in clinical practice and drug development
    Harper, Andrew R.
    Topol, Eric J.
    NATURE BIOTECHNOLOGY, 2012, 30 (11) : 1117 - 1124
  • [23] AHI PERSPECTIVES - FLEXIBLE DRUG LABELING AND ITS IMPACT ON THE DRUG DEVELOPMENT PROCESS - PRACTICALITY OF CLINICAL DEVELOPMENT
    COPELAND, DD
    JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 1995, 207 (07) : 895 - 896
  • [24] Impact of genomics on drug discovery and clinical medicine
    Emilien, G
    Ponchon, M
    Caldas, C
    Isacson, O
    Maloteaux, JM
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2000, 93 (07) : 391 - 423
  • [25] Impact of molecular medicine on drug development.
    Rudenko, L
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 220 : U217 - U217
  • [26] Sharing sensitive research data in the practice of personalised medicine
    Molnar Viktor
    Cs Sagi Judit
    Molnar Maria Judit
    ORVOSI HETILAP, 2023, 164 (21) : 811 - 819
  • [27] Personalised medicine in general practice: the example of raised cholesterol
    Qureshi, Nadeem
    Humphries, Steve E.
    Gray, Huon
    BRITISH JOURNAL OF GENERAL PRACTICE, 2018, 68 (667): : 68 - 69
  • [28] Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice
    Veldkamp, Saskia R.
    van Wijk, Femke
    van Royen-Kerkhof, Annet
    Jansen, Marc H. A.
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2024, 38 (03):
  • [29] Pharmacogenetics of drug metabolising enzymes: Importance for personalised medicine
    Oscarson, M
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, 41 (04) : 573 - 580
  • [30] Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models
    René Bruno
    Pascal Chanu
    Matts Kågedal
    Francois Mercier
    Kenta Yoshida
    Jérémie Guedj
    Chunze Li
    Ulrich Beyer
    Jin Y. Jin
    British Journal of Cancer, 2023, 129 : 1383 - 1388
12345